Bone drug showdown: which works better for Steroid-Weakened bones?
NCT ID NCT06472050
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at two osteoporosis medications—romosozumab and denosumab—in 54 people who take long-term steroids and have weak bones. Participants first received either romosozumab for 12 months followed by denosumab, or denosumab alone for 24 months. Then everyone stayed on denosumab for another 2 years. The goal was to see how their spine and hip bone density changed over 4 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Romosozumab (Evenity) and Denosumab (Prolia)
What this could lead to
If successful, this could show that switching from romosozumab to denosumab maintains or improves bone density better than denosumab alone for people on long-term steroids.
What could go wrong
This is a small, completed extension study with only 54 participants, so results may not apply to everyone. It only measures bone density, not actual fracture reduction.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Medicine, Tuen Mun Hospital
Hong Kong, China